If you received a retrievable IVC filter to help with the prevention of fatal lung clots, your health may have been impacted by complications that have been linked to these devices. A study conducted over a three-year period found that only 1.6% of retrievable IVC filters were properly retrieved. This means that the vast majority of patients with
Inferior Vena Cava (IVC) filters have been in use since the 1970s to prevent traveling blood clots. During that time, there have been hundreds of thousands of the filters implanted in patients across the country. Retractable IVC filters are designed to be used on a temporary basis, but they are often left in place long after they are needed.
For decades, doctors have helped prevent blood clots from reaching their patients’ hearts and lungs by inserting inferior vena cava (IVC) filters. However, IVC filter types are not all the same and some come with extra risks and potentially harmful side effects. Both retractable and permanent IVC filters are inserted into your vein via catheter, with retractable
If you have been or are currently being treated with an IVC filter, you know that the goal is to prevent blood clots from traveling to your lungs, brain, or heart that can cause strokes, heart attacks, or sudden respiratory distress. Unfortunately, numerous IVC filter risk factors make these filters potentially life-threatening. In fact, plaintiffs
“Low-T,” a condition created largely using aggressive pharmaceutical marketing efforts, is treated using supplemental testosterone therapy products. Of products used to treat “Low T,” AndroGel is the most commonly prescribed. However, due to questionable marketing tactics and an increased risk of potentially deadly side effects, several lawsuits have been filed against AndroGel’s manufacturer, AbbVie, Inc. The most recent AndroGel lawsuit updates have